IVD China last week: Danaher, Mindray, YHLO, BSBE, 3D Medicines x SINO-CELL BIOMED

Danaher's Northern China headquarters and synthetic biomanufacturing common technology platform land in Changping, Beijing

On January 16, 2024, Mr. Joakim Weidemanis, Executive Vice President and Global President of Danaher Global Medical Diagnostic Platform, attended the discussion and exchange in Zhongguancun Life Science Park, and signed a cooperation agreement on Danaher's Northern China headquarters and synthetic biological manufacturing common technology platform in Changping, Beijing

Mindray bio-medical's wholly-owned subsidiary intends to acquire 21.12% shares of APT Medical to enter the cardiovascular field

Shenzhen Mindray bio-medical electronics Co., Ltd. announced on the evening of January 28 that the company intends to acquire 21.12% shares of APT Medical through an agreement transfer through a wholly-owned subsidiary, with a total transfer amount of about 6.652 billion yuan. The actual controller of APT Medical undertakes to voluntarily, permanently and irrevocably relinquish the voting rights of its 10% shares of APT Medical on and after the date on which it receives the full share transfer price as agreed.

YHLO’s expected net profit of 340 million yuan - 390 million yuan in 2023

On January 23, Shenzhen YHLO Biotech Co., LTD. released a performance forecast, which is expected to achieve a net profit of 340 million yuan to 390 million yuan attributable to the owner of the parent company in 2023. 

In 2023, the operating income and gross margin of the company's corona-virus business decreased significantly compared with the same period last year. The cumulative installed capacity of the company's chemiluminescence instruments has gradually increased, and the revenue growth rate of the company's self-produced chemiluminescence and other self-produced products is in line with expectations.

BSBE’s net profit is expected to exceed 500 million yuan in 2023

On January 22, Beijing Strong Biotechnologies Inc. disclosed the 2023 annual performance forecast. 

Net profit attributable to shareholders is expected to be 506 million yuan to 545 million yuan in 2023, an increase of 30%-40%. Non-net profit is expected to be 492 million yuan to 531 million yuan, an increase of 27.76% to 37.86%.

3D Medicines signed a strategic cooperation with SINO-CELL BIOMED to jointly develop innovative drugs for tumor immune cell therapy

On January 26, Shanghai, China, the signing ceremony of strategic cooperation between 3D Medicines and SINO-CELL BIOMED was held in Shanghai. 

In this strategic cooperation, the two sides rely on their respective advantages to jointly research innovative treatment methods in the field of tumor immunotherapy and explore new cooperation models, hoping to provide better treatment options for tumor patients.